See more : Swire Properties Limited (SWPFF) Income Statement Analysis – Financial Results
Complete financial analysis of Profound Medical Corp. (PRN.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Profound Medical Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
- PROOF Acquisition Corp I (PACI) Income Statement Analysis – Financial Results
- ZERO Co., Ltd. (9028.T) Income Statement Analysis – Financial Results
- Maison Luxe, Inc. (MASN) Income Statement Analysis – Financial Results
- Sunwin Stevia International, Inc. (SUWN) Income Statement Analysis – Financial Results
- Anglo American plc (NGLB.DE) Income Statement Analysis – Financial Results
Profound Medical Corp. (PRN.TO)
About Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.20M | 6.68M | 6.87M | 7.30M | 4.23M | 1.91M | 3.90M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.82M | 3.66M | 3.92M | 3.83M | 1.81M | 1.31M | 2.41M | 187.01K | 119.03K | 0.00 |
| Gross Profit | 4.38M | 3.02M | 2.95M | 3.47M | 2.42M | 604.82K | 1.49M | -187.01K | -119.03K | 0.00 |
| Gross Profit Ratio | 60.87% | 45.22% | 42.95% | 47.56% | 57.27% | 31.66% | 38.18% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.38M | 14.69M | 15.28M | 9.91M | 9.54M | 7.54M | 7.66M | 7.43M | 3.70M | 2.31M |
| General & Administrative | 9.17M | 9.47M | 10.31M | 7.57M | 5.88M | 4.89M | 4.72M | 4.20M | 4.39M | 1.95M |
| Selling & Marketing | 9.45M | 8.47M | 7.65M | 4.86M | 2.14M | 3.00M | 3.12M | 0.00 | 0.00 | 0.00 |
| SG&A | 18.62M | 17.93M | 17.97M | 12.43M | 8.01M | 7.89M | 7.84M | 4.20M | 4.39M | 1.95M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.76K | 3.65K | 1.57K | 0.00 | 82.40K |
| Operating Expenses | 33.00M | 32.62M | 33.24M | 22.34M | 17.56M | 15.43M | 15.51M | 11.64M | 8.09M | 4.34M |
| Cost & Expenses | 35.82M | 36.28M | 37.16M | 26.17M | 19.36M | 16.74M | 17.92M | 11.64M | 8.09M | 4.34M |
| Interest Income | 1.64M | 803.00K | 205.00K | 692.00K | 368.46K | 355.20K | 101.58K | 117.25K | 99.24K | 8.53K |
| Interest Expense | 770.00K | 174.00K | 303.00K | 543.00K | 544.75K | 755.37K | 1.07M | 615.87K | 4.05M | 143.01K |
| Depreciation & Amortization | 1.15M | 2.09M | 2.36M | 2.06M | 2.01M | 1.68M | 876.42K | 187.01K | 85.77K | 84.90K |
| EBITDA | -26.78M | -34.63M | -28.65M | -19.50M | -12.53M | -13.24M | -16.78M | -15.56M | -11.15M | -6.31M |
| EBITDA Ratio | -372.01% | -381.29% | -413.39% | -227.72% | -312.49% | -693.11% | -339.11% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.62M | -29.60M | -30.29M | -18.86M | -15.13M | -14.83M | -17.63M | -15.64M | -11.22M | -4.34M |
| Operating Income Ratio | -397.50% | -443.08% | -440.72% | -258.26% | -357.63% | -776.04% | -451.94% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -81.00K | 3.74M | -303.00K | 2.42M | -171.00K | -247.73K | 2.72M | -672.30K | -1.10M | -3.60M |
| Income Before Tax | -28.70M | -28.38M | -30.59M | -21.58M | -15.31M | -15.07M | -14.91M | -12.14M | -12.32M | -7.94M |
| Income Before Tax Ratio | -398.62% | -424.82% | -445.13% | -295.41% | -361.79% | -789.01% | -382.26% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -128.00K | 287.00K | 105.00K | 45.00K | 148.42K | 169.44K | 58.94K | 10.46K | -523.22K | 410.41K |
| Net Income | -28.57M | -28.67M | -30.70M | -21.62M | -15.46M | -15.24M | -14.97M | -12.15M | -11.80M | -8.20M |
| Net Income Ratio | -396.85% | -429.11% | -446.66% | -296.03% | -365.30% | -797.88% | -383.77% | 0.00% | 0.00% | 0.00% |
| EPS | -1.35 | -1.38 | -1.50 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| EPS Diluted | -1.35 | -1.38 | -1.50 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| Weighted Avg Shares Out | 21.18M | 20.77M | 20.46M | 17.29M | 11.09M | 10.04M | 6.14M | 4.15M | 2.37M | 216.68K |
| Weighted Avg Shares Out (Dil) | 21.18M | 20.77M | 20.47M | 17.29M | 11.09M | 10.04M | 6.14M | 4.15M | 2.37M | 216.68K |
Source: https://incomestatements.info
Category: Stock Reports